FluWatch report: January 28 to February 3, 2024 (week 5)

On this page

• Influenza/influenza-like illness activity - Geographic spread
• Laboratory-confirmed influenza detections
• Syndromic / influenza-like illness surveillance
• Influenza outbreak surveillance
• Influenza severe outcomes surveillance
• Influenza strain characterization
• Antiviral resistance
• Influenza vaccine monitoring
• Provincial and international surveillance links

Influenza/influenza-like illness activity - Geographic spread

In week 5, 25 regions across Canada reported sporadic influenza activity and 18 regions in five provinces and territories reported localized influenza activity (N.L., N.S., N.B., Ont., and B.C.). For a second consecutive week, no regions reported widespread activity. Five regions reported no activity this week (Y.T., N.W.T., and Nvt.). (Figure 1). The proportion of regions reporting influenza activity and the intensity of reported activity has slightly decreased this week.

Number of Regions Reporting in week 5: 48 out of 53

Figure 1 - Text description

Province	Influenza Surveillance Region	Activity Level
N.L.	Eastern	Localized
N.L.	Labrador-Grenfell	Localized
N.L.	Central	Localized
N.L.	Western	Sporadic
P.E.I.	Prince Edward Island	Sporadic
N.S.	Zone 1 - Western	Localized
N.S.	Zone 2 - Northern	Localized
N.S.	Zone 3 - Eastern	Sporadic
N.S.	Zone 4 - Central	Sporadic
N.B.	Region 1	Localized
N.B.	Region 2	Localized
N.B.	Region 3	Localized
N.B.	Region 4	Localized
N.B.	Region 5	Sporadic
N.B.	Region 6	Localized
N.B.	Region 7	Sporadic
Que.	Nord-est	Sporadic
Que.	Québec et Chaudieres-Appalaches	Sporadic
Que.	Centre-du-Québec	Sporadic
Que.	Montréal et Laval	Sporadic
Que.	Ouest-du-Québec	Sporadic
Que.	Montérégie	Sporadic
Ont.	Central East	Localized
Ont.	Central West	Localized
Ont.	Eastern	Localized
Ont.	North East	Localized
Ont.	North West	Localized
Ont.	South West	Localized
Ont.	Toronto	Localized
Man.	Northern Regional	No Data
Man.	Prairie Mountain	No Data
Man.	Interlake-Eastern	No Data
Man.	Winnipeg	No Data
Man.	Southern Health	No Data
Sask.	North	Sporadic
Sask.	Central	Sporadic
Sask.	South	Sporadic
Alta.	North Zone	Sporadic
Alta.	Edmonton	Sporadic
Alta.	Central Zone	Sporadic
Alta.	Calgary	Sporadic
Alta.	South Zone	Sporadic
B.C.	Interior	Sporadic
B.C.	Fraser	Localized
B.C.	Vancouver Coastal	Sporadic
B.C.	Vancouver Island	Sporadic
B.C.	Northern	Sporadic
Y.T.	Yukon	No Activity
N.W.T.	North	No Activity
N.W.T.	South	No Activity
Nvt.	Qikiqtaaluk	No Activity
Nvt.	Kivalliq	Sporadic
Nvt.	Kitimeot	No Activity

Laboratory-confirmed influenza detections

The weekly percentage of tests positive for influenza (12.5% in week 5) has been stable over the past 4 weeks and remains below historical averages for this time of year. Influenza B detections have been steadily increasing over the past 4 weeks but remain low.

The following results were reported from sentinel laboratories across Canada in week 5 (Figures 2 and 3):

• A total of 4,276 laboratory detections (3,783 influenza A and 493 influenza B) were reported.
• Among subtyped influenza A detections (437), 73% (317) were influenza A(H1N1).
• Age information was reported for 3,195 detections. Adults over 65 years reported the highest proportion of detections, 30%. Detections in individuals aged 5-19 years old are stable following increases in recent weeks. Detections in the remaining age groups remain stable.

To date this season (August 27, 2023 to February 3, 2024):

• 62,073 influenza detections were reported, of which 96% (59,457) were influenza A and among subtyped influenza A detections (22,450), influenza A(H1N1) accounted for 86% of detections.
• 48,167 laboratory-confirmed influenza detections with age information were reported, of which 13,780 (29%) were in individuals aged 0-19 years old. Across adult age groups, adults over 65 years reported the highest detections, 30%, while similar proportions are being observed in adults 20-44 years old, 21% and adults 45-64 years, 21% (Figure 4).

For more detailed weekly and cumulative influenza data, see the text descriptions for Figures 2 and 3 or the Respiratory Virus Detections in Canada Report.

Number of Laboratories Reporting in Week 5: 35 out of 35

Figure 2 - Text description

Surveillance Week	A(Unsubtyped)	A(H3N2)	A(H1N1)	Influenza B	Percent Positive A	Percent Positive B
35	19	27	51	9	0.7	0.1
36	12	11	50	9	0.4	0.1
37	28	14	46	6	0.5	0.0
38	28	15	57	4	0.5	0.0
39	18	10	74	20	0.5	0.1
40	39	20	80	13	0.6	0.1
41	43	10	50	7	0.5	0.0
42	59	15	96	19	0.7	0.1
43	99	29	136	23	1.2	0.1
44	291	53	315	25	2.6	0.1
45	685	62	539	37	4.9	0.1
46	1032	103	961	47	7.2	0.2
47	1162	134	1306	35	8.8	0.1
48	1712	165	1857	85	11.6	0.3
49	2383	208	2220	99	14.8	0.3
50	3024	262	2536	139	15.3	0.4
51	3983	352	2549	184	16.8	0.5
52	4914	416	2398	219	18.2	0.5
1	4163	450	1718	259	14.5	0.6
2	3240	342	845	225	11.2	0.6
3	2661	236	617	279	10.3	0.8
4	3064	113	465	380	11.1	1.1
5	3054	120	317	493	11.1	1.5
6	0	0	0	0	0.0	0.0
7	0	0	0	0	0.0	0.0
8	0	0	0	0	0.0	0.0
9	0	0	0	0	0.0	0.0
10	0	0	0	0	0.0	0.0
11	0	0	0	0	0.0	0.0
12	0	0	0	0	0.0	0.0
13	0	0	0	0	0.0	0.0
14	0	0	0	0	0.0	0.0
15	0	0	0	0	0.0	0.0
16	0	0	0	0	0.0	0.0
17	0	0	0	0	0.0	0.0
18	0	0	0	0	0.0	0.0
19	0	0	0	0	0.0	0.0
20	0	0	0	0	0.0	0.0
21	0	0	0	0	0.0	0.0
22	0	0	0	0	0.0	0.0
23	0	0	0	0	0.0	0.0
24	0	0	0	0	0.0	0.0
25	0	0	0	0	0.0	0.0
26	0	0	0	0	0.0	0.0
27	0	0	0	0	0.0	0.0
28	0	0	0	0	0.0	0.0
29	0	0	0	0	0.0	0.0
30	0	0	0	0	0.0	0.0
31	0	0	0	0	0.0	0.0
32	0	0	0	0	0.0	0.0
33	0	0	0	0	0.0	0.0
34	0	0	0	0	0.0	0.0

The shaded area represents the maximum and minimum number of influenza tests or percentage of tests positive reported by week from seasons 2014-2015 to 2019-2020. Data from week 11 of the 2019-2020 season onwards are excluded from the historical comparison due to the COVID-19 pandemic.

The epidemic threshold is 5% tests positive for influenza. When it is exceeded, and a minimum of 15 weekly influenza detections are reported, a seasonal influenza epidemic is declared.

Figure 3 - Text description

Surveillance Week	Percentage of tests positive, 2023-2024	Percentage of tests positive, 2022-2023	Percentage of tests positive, 2021-2022	Maximum Percentage of Tests Positive	Minimum Percentage of Tests Positive	Average Percentage of Tests Positive
35	0.8	0.2	0.0	1.9	0.1	0.8
36	0.5	0.2	0.0	2.3	0.3	1.1
37	0.5	0.3	0.0	1.8	0.4	1.0
38	0.5	0.5	0.0	2.4	0.6	1.3
39	0.6	0.7	0.0	3.0	0.6	1.7
40	0.7	1.0	0.0	2.3	1.1	1.7
41	0.5	1.4	0.1	3.0	1.3	1.7
42	0.8	2.4	0.1	3.4	0.9	2.2
43	1.3	5.5	0.1	5.3	0.8	2.8
44	2.7	10.8	0.2	8.4	1.2	3.7
45	5.1	16.2	0.1	10.1	1.4	4.6
46	7.4	20.3	0.2	14.1	1.5	6.0
47	8.9	24.3	0.2	15.4	1.4	7.7
48	11.9	24.1	0.3	18.2	0.8	10.6
49	15.0	21.2	0.3	19.3	1.6	12.9
50	15.7	17.4	0.3	27.0	2.4	16.4
51	17.2	12.5	0.2	29.1	3.3	20.0
52	18.7	8.0	0.1	34.5	4.3	24.4
1	15.1	4.6	0.1	31.7	5.9	23.5
2	11.7	2.3	0.1	29.1	7.1	23.0
3	11.1	1.5	0.1	30.1	12.2	23.7
4	12.2	1.1	0.1	29.5	15.9	24.0
5	12.5	1.0	0.0	30.6	19.6	24.9
6	-	1.0	0.0	32.4	17.9	25.0
7	-	0.9	0.0	32.5	16.3	25.1
8	-	1.1	0.1	32.9	17.6	25.2
9	-	1.3	0.1	34.3	16.8	24.4
10	-	1.4	0.2	36.0	16.1	23.3
11	-	1.7	0.3	31.4	16.2	21.4
12	-	1.9	0.9	30.0	15.0	20.1
13	-	2.4	1.5	28.3	14.5	19.6
14	-	2.2	2.5	26.2	12.7	19.1
15	-	2.5	3.9	20.7	12.0	16.3
16	-	2.4	7.0	18.5	11.6	14.5
17	-	2.4	9.7	17.3	9.8	12.8
18	-	2.3	11.3	13.0	7.9	10.3
19	-	2.1	12.6	12.0	5.0	9.0
20	-	2.1	10.4	9.1	3.2	7.2
21	-	1.6	9.8	7.5	3.0	5.6
22	-	1.6	8.4	4.9	2.2	3.9
23	-	1.3	7.0	4.4	0.9	2.9
24	-	1.1	5.0	4.4	0.8	2.3
25	-	1.0	3.0	4.0	0.6	1.9
26	-	0.7	2.3	3.0	0.7	1.8
27	-	0.6	1.2	2.8	0.4	1.4
28	-	0.8	0.8	1.8	0.4	0.9
29	-	0.5	0.7	1.5	0.5	1.1
30	-	0.5	0.4	1.5	0.5	0.9
31	-	0.5	0.3	1.9	0.6	1.1
32	-	0.7	0.2	1.2	0.5	0.9
33	-	0.7	0.2	1.7	0.4	0.9
34	-	0.6	0.2	1.6	0.4	0.9

Laboratory data notes:

Testing for influenza and other respiratory viruses has been influenced by the COVID-19 pandemic. Changes in laboratory testing practices may affect the comparability of data to previous seasons.

Due to different testing protocols of laboratories across Canada, some influenza A subtype detection counts may not be included in total influenza A detection counts and percent positivity calculations.

Figure 4 - Text description

a) Proportion of influenza A and B by age-group

Age Group	Proportion of Influenza A	Proportion of Influenza B	Total Number Influenza Detections
0 to 4	96.1%	3.9%	6971
5 to 19	89.0%	11.0%	6809
20 to 44	93.2%	6.8%	9886
45 to 64	98.1%	1.9%	10251
65+	99.0%	1.0%	14250

b) Proportion of subtyped influenza A(H1N1) and A(H3N2) by age-group

Age Group	Proportion of A(H1N1)	Proportion of A(H3N2)	Total Number of Subtyped Influenza Detections
0 to 4	91.6%	8.4%	2654
5 to 19	89.7%	10.3%	2631
20 to 44	85.3%	14.7%	3746
45 to 64	92.4%	7.6%	3785
65+	83.2%	16.8%	4837

Syndromic / influenza-like illness surveillance

Healthcare practitioners sentinel surveillance

In week 5, 2.11% of visits to healthcare professionals were due to influenza-like illness (ILI) (Figure 5). The percentage of visits for ILI has increased the past two weeks but is within expected levels for this time of year.

ILI symptoms are not specific to any one respiratory pathogen and can be due to influenza, or other respiratory viruses, including respiratory syncytial virus and SARS-CoV-2, the virus that causes COVID-19. This makes the percentage of visits for ILI an important indicator of overall respiratory illness morbidity in the community in the presence of co-circulating viruses.

This indicator should be interpreted with caution as there have been a smaller number of sentinels reporting compared to previous seasons.

Number of Sentinels Reporting in Week 5: 42

The shaded area represents the maximum and minimum percentage of visits for ILI reported by week from seasons 2014-2015 to 2019-2020. Data from week 11 of the 2019-2020 season onwards are excluded from the historical comparison due to the COVID-19 pandemic.

Figure 5 - Text description

Surveillance Week	2023-2024	2022-2023	2021-2022	Average	Min	Max
35	0.5%	0.6%	0.1%	0.6%	0.4%	0.9%
36	0.4%	1.2%	0.2%	0.6%	0.4%	0.9%
37	0.8%	0.6%	0.4%	0.7%	0.5%	1.0%
38	0.8%	0.9%	0.3%	0.7%	0.6%	1.0%
39	0.9%	1.0%	0.4%	0.9%	0.5%	1.2%
40	0.6%	0.5%	0.2%	1.2%	0.8%	1.7%
41	1.6%	1.1%	0.4%	1.7%	0.8%	2.8%
42	1.0%	1.2%	0.5%	1.6%	1.2%	2.1%
43	0.8%	0.9%	0.3%	1.2%	0.8%	1.7%
44	1.3%	0.6%	0.3%	1.2%	0.7%	1.7%
45	1.2%	1.0%	0.4%	1.2%	0.9%	1.5%
46	2.0%	0.9%	0.8%	1.4%	1.2%	1.8%
47	1.7%	0.7%	0.3%	1.6%	1.1%	2.2%
48	2.0%	1.1%	0.5%	1.5%	1.1%	2.2%
49	2.0%	0.9%	0.5%	1.7%	1.0%	2.8%
50	2.2%	1.1%	0.4%	1.5%	1.1%	1.7%
51	2.0%	1.7%	0.5%	1.9%	1.4%	2.7%
52	1.8%	1.5%	0.5%	2.0%	1.0%	3.1%
1	1.8%	2.1%	0.7%	3.4%	1.9%	5.4%
2	2.4%	1.6%	0.4%	3.4%	1.8%	5.7%
3	1.3%	1.4%	0.2%	2.3%	1.3%	3.7%
4	1.6%	0.9%	0.3%	2.0%	1.1%	2.9%
5	2.1%	1.0%	0.2%	2.1%	1.4%	3.1%
6	-	0.7%	0.5%	2.4%	1.4%	4.0%
7	-	0.7%	0.3%	2.4%	0.9%	3.5%
8	-	0.8%	0.2%	2.3%	0.8%	3.4%
9	-	0.7%	0.2%	2.3%	0.9%	3.1%
10	-	0.9%	0.2%	2.0%	1.0%	2.8%
11	-	0.6%	0.2%	1.9%	1.1%	2.8%
12	-	0.8%	0.3%	1.6%	0.6%	2.6%
13	-	1.2%	0.4%	1.6%	1.1%	2.6%
14	-	1.1%	0.2%	1.7%	1.1%	3.0%
15	-	1.2%	0.3%	1.3%	0.9%	1.9%
16	-	1.5%	0.3%	1.2%	0.8%	1.7%
17	-	1.3%	0.4%	1.2%	0.7%	1.7%
18	-	1.8%	0.5%	1.3%	0.5%	2.0%
19	-	1.7%	0.3%	0.9%	0.6%	1.3%
20	-	1.5%	0.5%	1.1%	0.6%	1.5%
21	-	1.4%	0.3%	0.9%	0.5%	1.3%
22	-	1.0%	0.3%	0.7%	0.3%	1.0%
23	-	1.1%	0.2%	0.8%	0.6%	1.0%
24	-	1.3%	0.2%	0.7%	0.6%	1.0%
25	-	1.0%	0.2%	0.6%	0.4%	0.8%
26	-	0.8%	0.2%	0.8%	0.5%	1.4%
27	-	1.7%	0.3%	0.6%	0.5%	0.7%
28	-	1.0%	0.1%	0.7%	0.5%	1.3%
29	-	0.9%	0.3%	0.9%	0.6%	1.7%
30	-	1.3%	0.2%	0.6%	0.2%	0.9%
31	-	0.9%	0.2%	0.4%	0.2%	0.6%
32	-	0.9%	0.2%	0.8%	0.3%	1.2%
33	-	0.8%	0.3%	0.7%	0.4%	1.3%
34	-	1.0%	0.5%	0.7%	0.4%	1.5%

FluWatchers

In week 5, 9,051 participants reported to FluWatchers, of which 1.5% reported symptoms of cough and fever (Figure 6). The percentage of FluWatchers reporting cough and fever has been stable over the past 4 weeks and remains below expected levels for this time of year.

The reports of cough and fever are not specific to any one respiratory pathogen and can be due to influenza, or other respiratory viruses, including respiratory syncytial virus, rhinovirus, and SARS-CoV-2, the virus that causes COVID-19. This makes the proportion of individuals reporting cough and fever an important indicator of overall respiratory illness activity in the community in the presence of co-circulating viruses.

FluWatchers reporting is not impacted by changes in health services or health seeking behaviours.

Among the 133 participants who reported cough and fever:

• 15% consulted a healthcare professional.
• 74% reported days missed from work or school, resulting in an average of 2.3 missed days from work or school among those 98 participants.

Yukon had the highest participation rate this week (53 participants per 100,000 population) and the neighbourhood with postal code K0A had the highest number of participants (116). See what is happening in your neighbourhood! Downloadable datasets are also available on Open Maps.

If you are interested in becoming a FluWatcher, sign up today.

Number of Participants Reporting in Week 5: 9,051

The shaded area represents the maximum and minimum percentage of percentage of participants reporting cough and fever by week, from seasons 2014-2015 to 2019-2020. Data from week 11 of the 2019-2020 season onwards are excluded from the historical comparison due to the COVID-19 pandemic

Figure 6 - Text description

Surveillance Week	2023-2024	2022-2023	2021-2022	Average	Min	Max
35	1.1%	1.3%	0.2%	-	-	-
36	1.2%	1.2%	0.3%	-	-	-
37	1.5%	1.6%	0.5%	-	-	-
38	2.0%	1.8%	0.5%	-	-	-
39	2.3%	2.3%	0.5%	-	-	-
40	1.8%	2.4%	0.6%	2.5%	2.2%	2.7%
41	1.6%	2.0%	0.5%	2.2%	1.8%	2.6%
42	1.7%	2.0%	0.4%	1.8%	1.6%	2.0%
43	1.7%	2.3%	0.5%	1.9%	1.5%	2.2%
44	1.9%	2.6%	0.5%	1.6%	1.4%	1.8%
45	1.9%	3.0%	0.5%	1.8%	1.4%	2.3%
46	1.9%	2.9%	0.4%	1.8%	1.2%	2.2%
47	2.0%	3.1%	0.6%	1.9%	1.4%	2.4%
48	2.2%	3.1%	0.5%	2.4%	1.7%	3.4%
49	2.2%	2.7%	0.4%	2.6%	2.0%	3.2%
50	2.5%	2.1%	0.6%	2.9%	2.1%	3.8%
51	2.4%	2.4%	1.0%	3.2%	2.5%	3.9%
52	3.0%	2.1%	1.5%	4.0%	2.8%	5.4%
1	2.2%	1.7%	1.1%	3.8%	2.9%	4.8%
2	1.4%	1.3%	1.0%	2.9%	1.9%	3.9%
3	1.4%	1.3%	0.8%	3.3%	2.3%	4.8%
4	1.3%	1.2%	0.6%	3.1%	2.1%	4.2%
5	1.5%	1.1%	0.6%	3.2%	2.6%	3.6%
6	-	1.4%	0.5%	3.5%	2.8%	4.3%
7	-	1.3%	0.4%	3.2%	2.6%	3.8%
8	-	1.3%	0.5%	3.1%	2.5%	3.6%
9	-	1.4%	0.5%	2.8%	2.4%	3.5%
10	-	1.5%	0.6%	2.6%	2.1%	3.1%
11	-	1.5%	0.9%	2.3%	1.9%	2.6%
12	-	1.3%	1.2%	2.6%	2.5%	2.8%
13	-	1.5%	1.8%	2.5%	2.0%	3.1%
14	-	1.3%	2.3%	2.1%	1.3%	2.6%
15	-	1.4%	1.9%	1.8%	1.6%	1.9%
16	-	1.2%	1.9%	2.0%	1.5%	2.4%
17	-	1.2%	1.6%	1.7%	1.4%	2.3%
18	-	1.1%	1.4%	1.5%	1.2%	2.1%
19	-	0.9%	1.3%	-	-	-
20	-	1.0%	1.2%	-	-	-
21	-	0.9%	1.2%	-	-	-
22	-	0.7%	1.2%	-	-	-
23	-	0.9%	1.2%	-	-	-
24	-	0.9%	1.3%	-	-	-
25	-	0.7%	1.3%	-	-	-
26	-	0.9%	1.8%	-	-	-
27	-	0.8%	2.0%	-	-	-
28	-	0.6%	1.9%	-	-	-
29	-	0.6%	1.8%	-	-	-
30	-	0.7%	1.6%	-	-	-
31	-	1.0%	1.3%	-	-	-
32	-	0.9%	1.2%	-	-	-
33	-	0.9%	1.4%	-	-	-
34	-	1.2%	1.3%	-	-	-

Influenza outbreak surveillance

In week 5, 69 laboratory-confirmed influenza outbreaks were reported. All outbreaks were associated with influenza A.

To date this season (August 27, 2023 to February 3, 2024):

• 790 laboratory-confirmed influenza outbreaks have been reported
  • 410 were in LTC facilities (52%)
  • 220 were in acute care facilities (28%)
  • 160 were in a facility categorized as 'other' (20%)
  • 768 outbreaks were due to influenza A and four outbreaks were due to influenza B; an additional 4 outbreaks were due to a mix of influenza A and influenza B and 2 outbreaks were untyped.
  • Among outbreaks with subtyping information (177), influenza A(H1N1) was detected in 91% of the outbreaks
• 67 ILI outbreaks have been reported
  • All ILI outbreaks have been reported in schools and/or daycares

Outbreaks of ILI are not specific to any one respiratory pathogen and can be due influenza, or other respiratory viruses, including respiratory syncytial virus, rhinovirus, COVID-19, or a mixture of viruses.

Number of provinces and territories^{Footnote 1} reporting in week 5: 12 out of 13

Figure 7 - Text description

Surveillance Week	Acute Care Facilities	Long Term Care Facilities	Other	Schools and Daycares	Remote and/or Isolated Communities
35	0	1	1	0	0
36	0	0	0	0	0
37	0	2	0	0	0
38	0	2	0	0	0
39	0	1	0	0	0
40	0	2	0	0	0
41	0	1	0	0	0
42	0	2	0	0	0
43	0	3	1	0	0
44	2	6	2	0	0
45	1	2	5	0	0
46	8	4	1	0	0
47	6	5	6	0	0
48	8	12	6	0	0
49	12	22	11	0	0
50	13	21	19	0	0
51	11	23	17	0	0
52	6	48	17	0	0
1	31	64	22	0	0
2	26	59	22	0	0
3	21	34	9	0	0
4	52	61	10	0	0
5	23	35	11	0	0
6	0	0	0	0	0
7	0	0	0	0	0
8	0	0	0	0	0
9	0	0	0	0	0
10	0	0	0	0	0
11	0	0	0	0	0
12	0	0	0	0	0
13	0	0	0	0	0
14	0	0	0	0	0
15	0	0	0	0	0
16	0	0	0	0	0
17	0	0	0	0	0
18	0	0	0	0	0
19	0	0	0	0	0
20	0	0	0	0	0
21	0	0	0	0	0
22	0	0	0	0	0
23	0	0	0	0	0
24	0	0	0	0	0
25	0	0	0	0	0
26	0	0	0	0	0
27	0	0	0	0	0
28	0	0	0	0	0
29	0	0	0	0	0
30	0	0	0	0	0
31	0	0	0	0	0
32	0	0	0	0	0
33	0	0	0	0	0
34	0	0	0	0	0

Influenza severe outcomes surveillance

Provincial/territorial influenza hospitalizations and deaths

In week 5, 74 influenza-associated hospitalizations, 9 ICU admissions, and less than five influenza-associated deaths were reported by participating provinces and territories^{Footnote 2}. The majority of hospitalizations reported in week 5 were in adults (84%).

To date this season (August 27, 2023 to February 3, 2024), 3,523 influenza-associated hospitalizations were reported by participating provinces and territories:

• 98% of the hospitalizations were associated with influenza A.
• Of the cases with subtype information (2,458), 95% were associated with influenza A(H1N1).
• Adults aged 65 years of age and older accounted for 49% of reported hospitalizations. The highest cumulative hospitalization rates were among adults 65 years of age and older (116/100,000) and children under 5 years of age (70/100,000).

To date this season (August 27, 2023 to February 3, 2024), 399 ICU admissions and 194 influenza-associated deaths were reported.

• Adults aged 45-64 years of age and 65 years of age and older accounted for 39% and 32% of reported ICU admissions respectively.
• Adults aged 65 years of age and older accounted for 71% of reported deaths.

Number of provinces and territories reporting in week 5: 8 out of 9

Figure 8 - Text description

Surveillance Week	0-4 yrs	5-19 yrs	20-44 yrs	45-64 yrs	65+ yrs	Overall
35	-	0.1	-	0.0	0.2	0.0
36	-	0.1	-	0.0	0.4	0.1
37	-	0.1	-	0.2	0.7	0.2
38	-	0.1	0.0	0.2	0.8	0.2
39	0.4	0.1	0.1	0.3	1.0	0.3
40	0.4	0.1	0.1	0.4	1.6	0.4
41	0.4	0.3	0.2	0.5	1.8	0.6
42	0.9	0.4	0.2	0.6	2.0	0.7
43	0.9	0.7	0.3	0.9	2.8	1.0
44	2.7	1.1	0.5	1.4	4.7	1.7
45	4.0	1.7	0.9	2.5	7.8	2.8
46	9.0	2.4	1.6	4.5	13.0	4.9
47	16.1	3.7	2.5	7.6	19.4	7.7
48	24.2	5.6	4.1	12.0	28.1	11.6
49	36.1	7.3	6.2	16.9	41.7	16.8
50	44.4	9.3	8.2	22.3	57.0	22.3
51	51.8	11.6	9.6	27.7	71.0	27.4
52	58.3	13.0	11.1	32.3	86.3	32.3
1	61.7	13.6	12.0	35.9	98.8	36.0
2	64.8	14.0	12.5	37.5	104.3	37.7
3	66.6	14.2	12.8	38.7	109.0	39.1
4	68.2	14.8	13.2	39.6	112.5	40.2
5	69.9	15.4	13.4	40.5	116.2	41.4
6	-	-	-	-	-	-
7	-	-	-	-	-	-
8	-	-	-	-	-	-
9	-	-	-	-	-	-
10	-	-	-	-	-	-
11	-	-	-	-	-	-
12	-	-	-	-	-	-
13	-	-	-	-	-	-
14	-	-	-	-	-	-
15	-	-	-	-	-	-
16	-	-	-	-	-	-
17	-	-	-	-	-	-
18	-	-	-	-	-	-
19	-	-	-	-	-	-
20	-	-	-	-	-	-
21	-	-	-	-	-	-
22	-	-	-	-	-	-
23	-	-	-	-	-	-
24	-	-	-	-	-	-
25	-	-	-	-	-	-
26	-	-	-	-	-	-
27	-	-	-	-	-	-
28	-	-	-	-	-	-
29	-	-	-	-	-	-
30	-	-	-	-	-	-
31	-	-	-	-	-	-
32	-	-	-	-	-	-
33	-	-	-	-	-	-
34	-	-	-	-	-	-
35	-	0.1	-	0.0	0.2	0.0
36	-	0.1	-	0.0	0.4	0.1
37	-	0.1	-	0.2	0.7	0.2
38	-	0.1	0.0	0.2	0.8	0.2
39	0.4	0.1	0.1	0.3	1.0	0.3
40	0.4	0.1	0.1	0.4	1.6	0.4
41	0.4	0.3	0.2	0.5	1.8	0.6
42	0.9	0.4	0.2	0.6	2.0	0.7
43	0.9	0.7	0.3	0.9	2.8	1.0
44	2.7	1.1	0.5	1.4	4.7	1.7
45	4.0	1.7	0.9	2.5	7.8	2.8
46	9.0	2.4	1.6	4.5	13.0	4.9
47	16.1	3.7	2.5	7.6	19.4	7.7
48	24.2	5.6	4.1	12.0	28.1	11.6
49	36.1	7.3	6.2	16.9	41.6	16.8
50	44.6	9.3	8.2	22.3	56.9	22.3
51	52.0	11.6	9.6	27.6	70.9	27.4
52	58.5	13.0	11.1	32.2	86.2	32.3
1	61.7	13.6	12.0	35.8	98.6	35.9
2	64.8	14.0	12.5	37.4	104.0	37.7
3	66.6	14.2	12.8	38.6	108.7	39.0
4	68.1	14.8	13.2	39.5	112.7	40.3
5	-	-	-	-	-	-
6	-	-	-	-	-	-
7	-	-	-	-	-	-
8	-	-	-	-	-	-
9	-	-	-	-	-	-
10	-	-	-	-	-	-
11	-	-	-	-	-	-
12	-	-	-	-	-	-
13	-	-	-	-	-	-
14	-	-	-	-	-	-
15	-	-	-	-	-	-
16	-	-	-	-	-	-
17	-	-	-	-	-	-
18	-	-	-	-	-	-
19	-	-	-	-	-	-
20	-	-	-	-	-	-
21	-	-	-	-	-	-
22	-	-	-	-	-	-
23	-	-	-	-	-	-
24	-	-	-	-	-	-
25	-	-	-	-	-	-
26	-	-	-	-	-	-
27	-	-	-	-	-	-
28	-	-	-	-	-	-
29	-	-	-	-	-	-
30	-	-	-	-	-	-
31	-	-	-	-	-	-
32	-	-	-	-	-	-
33	-	-	-	-	-	-
34	-	-	-	-	-	-

Sentinel Pediatric Influenza Severe Outcomes

For the 2023-2024 season, data on pediatric influenza associated severe outcomes are provided by the Surveillance Program for Rapid Identification and Tracking of Infectious Diseases in kids (SPRINT-KIDS) Network^{Footnote 3}. The SPRINT-KIDS sentinel pediatric (≤18 years) hospital network provides severe outcome monitoring in both the emergency department and inpatient facilities and consists of 15 pediatric hospitals across 8 provinces in Canada (all provinces with the exception of New Brunswick and Prince Edward Island).

Emergency and Inpatient Influenza Testing

In week 5, 977 tests were conducted for influenza in emergency departments and inpatient wards from 7/15 sites:

• 192 tests (19.7%) were positive for influenza.
• The majority were influenza A (n=170, 89%).

To date this season (October 1, 2023 to February 3, 2024):

• 18,040 tests have been conducted for influenza across 12 sites^{Footnote 4}.
• 2,327 tests were positive for influenza.
• The majority were influenza A (n=2,231, 96%).

Hospitalizations

In week 5, 31 influenza-associated pediatric hospitalizations were reported from a total of 192 positive influenza tests from 7/15 sites:

• All but two of the hospitalizations were due to influenza A.

To date this season (October 1, 2023 to February 3, 2024):

• 547 influenza-associated pediatric hospitalizations were reported from a total of 2,264 positive influenza tests across 8 sites^{Footnote 4}.
• The majority were influenza A (n=532, 97%).

Influenza strain characterization

Since September 1, 2023, the National Microbiology Laboratory Branch (NMLB) has characterized 719 influenza viruses (121 A(H3N2), 520 A(H1N1), and 78 influenza B) received from Canadian laboratories.

Antigenic Characterization

Changes in circulating influenza viruses are monitored by antigenic characterization. Antigenic characterization results show how similar the circulating viruses are to reference viruses. Reference viruses represent strains included in the current seasonal influenza vaccine.

Influenza A(H1N1)

A/Wisconsin/67/2022 is the influenza A(H1N1) component of the 2023-2024 Northern Hemisphere influenza vaccine.

• 509 H1N1 viruses were characterized as antigenically similar to A/Wisconsin/67/2022-like with antisera produced against cell-grown A/Wisconsin/67/2022.
• 11 influenza A(H1N1) showed reduced titer with antisera raised against cell-grown A/Wisconsin/67/2022.

Influenza A(H3N2)

A/Darwin/6/2021 (H3N2)-like virus is the influenza A(H3N2) component of the 2023-2024 Northern Hemisphere influenza vaccine.

• 117 influenza A(H3N2) were antigenically similar to A/Darwin/6/2021 (H3N2)-like virus using antisera raised against cell-grown A/Darwin/6/2021 (H3N2)-like virus.
• 4 influenza A(H3N2) showed reduced titer with antisera raised against cell-grown A/Darwin/6/2021 (H3N2)-like virus.

Influenza B

Influenza B viruses can be divided into two antigenically distinct lineages represented by B/Yamagata/16/88 and B/Victoria/2/87 viruses. The recommended influenza B components for the 2023-2024 Northern Hemisphere influenza vaccine are B/Austria/1359417/2021 (Victoria lineage) and B/Phuket/3073/2013 (Yamagata lineage)

• 78 viruses characterized were antigenically similar to B/Austria/1359417/2021.

Genetic Characterization

Genetic characterization is used to determine how similar gene sequences of circulating influenza viruses are to the sequences of the vaccine components used in the current seasonal influenza vaccine.

Since September 1, 2023, NML has genetically characterized 597 influenza viruses.

Antiviral resistance

The National Microbiology Laboratory has not yet reported antiviral resistance results for influenza viruses collected during the 2023-2024 season.

Oseltamivir

643 influenza viruses (102 H3N2, 483 H1N1 and 58 influenza B) were tested for resistance to oseltamivir.

• One of the 483 influenza A (H1N1) viruses was resistant to oseltamivir
• All influenza A(H3N2) viruses and B viruses were sensitive to oseltamivir.

Zanamivir

642 influenza viruses (101 H3N2, 483 H1N1 and 58 influenza B) were tested for resistance to zanamivir.

• All influenza viruses were sensitive to zanamivir.

Influenza vaccine monitoring

Vaccine monitoring refers to activities related to the monitoring of influenza vaccination coverage and vaccine effectiveness.

Vaccination coverage

Influenza vaccine coverage estimates for the 2023-2024 season are anticipated to be available in February or March 2024.

Vaccine effectiveness

Influenza vaccine effectiveness estimates for the 2023-2024 season are anticipated to be available in February or March 2024.

Provincial and international surveillance links

See Influenza surveillance resources

Notes

The data in the FluWatch report represent surveillance data available at the time of writing. All data are preliminary and may change as updates are received.

To learn more about the FluWatch program, see the Overview of influenza monitoring in Canada page.

For more information on the flu, see our Flu (influenza) web page.

We would like to thank all the FluWatch surveillance partners participating in this year's influenza surveillance program.

This report is available on the Government of Canada Influenza webpage.

Ce rapport est disponible dans les deux langues officielles.